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Abstract
This large, prospective, noninterventional study assessed the efﬁcacy and safety of sorafenib in patients with
advanced renal cell carcinoma (RCC) in a clinical practice setting. Sorafenib was generally well tolerated, with
no unexpected adverse events observed, and provided clinical beneﬁt in this diverse patient population.
Background: Patients with advanced renal cell carcinoma in routine clinical practice can differ considerably from
those in phase III studies. Patients and Methods: PREDICT (Patient characteristics in REnal cell carcinoma and Daily
practICe Treatment with sorafenib) was a prospective, noninterventional study of open-label sorafenib for the treat-
ment of advanced RCC conducted in 18 countries. Patient characteristics, therapy duration, tumor status, and
tolerability were assessed at baseline and during routine follow-up. Results: Overall, 2599 patients were evaluable for
safety and 2311 for efﬁcacy. The diverse population included patients with brain metastases (5%), non-clear-cell
histologies (17%), high Memorial Sloan-Kettering Cancer Center risk score (11%), poor Eastern Cooperative Oncology
Group performance status (PS  2, 29%), and patients with no previous nephrectomy (16%) or no previous systemic
therapy (37%). The median duration of sorafenib therapy was 7.3 months and was similar in clinically relevant sub-
groups (eg, patients with PS 2, brain metastases, or concomitant hypertension or diabetes [range, 6.7-7.0 months]).
The median duration of therapy was shorter for patients with PS 3 or non-clear-cell histologies (4.6 and 4.8 months,
respectively). The most common drug-related adverse events were handefoot skin reaction (20%), diarrhea (17%),
and rash (8%). Conclusion: Sorafenib was generally well tolerated and provided clinical beneﬁt in a large, diverse
population of patients with advanced RCC treated in routine clinical practice.
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Systemic therapy for advanced renal cell carcinoma (RCC) has
evolved rapidly since 2005, with 7 targeted therapies approved and
several more agents in late-stage clinical development. Sorafenib, a
multitargeted tyrosine kinase inhibitor (TKI) with antiangiogenic and
antiproliferative properties,1 was one of the ﬁrst targeted therapies to*This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).
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1receive widespread regulatory approval for the treatment of advanced
RCC. The efﬁcacy and tolerability of sorafenib were demonstrated in
the phase III TARGET (Treatment Approaches in Renal cancer
Global Evaluation Trial) in 903 patients with previously treated
advanced RCC.2,3 Median progression-free survival (PFS) with
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(2.8 months; P < .01). More recently, sorafenib has been used as a
comparator in several phase III trials assessing ﬁrst-, second-, and
third-line treatment options for patients with advanced RCC. The
median PFS values for sorafenib in these trials ranged from 9.1
months in treatment-naive patients to 3.6 months in patients
receiving sorafenib as third-line treatment.4,5 Median PFS for
sorafenib in the second-line setting was 3.9e4.7 months in recent
randomized phase III trials with sorafenib as the comparator.6,7
Phase III studies provide valuable data regarding the efﬁcacy and
tolerability of investigational agents. However, they employ strict
inclusion criteria, resulting in patient populations that are usually
more homogeneous than those treated in routine clinical practice. For
example, the phase III RCC studies for the targeted agents sorafenib,
sunitinib, bevacizumab, pazopanib, and everolimus all excluded
patients with brain metastases and patients with poor performance
status (either Eastern Cooperative Oncology Group performance
status [ECOG PS] 2 or Karnofsky score< 70%).2,8-12 In addition,
although a large proportion of patients with RCC are aged  65
years,13 elderly patients have tended to be underrepresented in phase
III trials, possibly owing to an increased incidence of comorbidities
or concomitant medications that may make them ineligible for
such studies.14 Indeed, a population-based retrospective analysis
indicated that clinical outcomes were worse for patients with
advanced RCC who would typically be ineligible for clinical trials,
than for those who would be eligible for inclusion.15 Insights into the
safety and activity of sorafenib in a larger population of patients
with advanced RCC were gathered from 2 expanded access
programs prior to regulatory approval of sorafenib (theNorthAmerica
[NA-] and European [EU-] Advanced Renal Cell Carcinoma
Sorafenib [ARCCS] studies).16-18 Although the inclusion criteria
for patients enrolled in these expanded access programs were broader
than those used for the TARGET study, some exclusion criteria
meant that the studied populations were not fully representative of
patients encountered in routine clinical practice settings. For example,
patients with cardiac arrhythmias, active coronary artery disease
or ischemia, or uncontrolled hypertension were excluded from the
NA-ARCCS, and< 1% of patients had received prior TKI therapy.18
Patients with ECOG PS  2 were excluded from the EU-ARCCS
study.16
The PREDICT (Patient characteristics in REnal cell carcinoma
and Daily practICe Treatment with sorafenib) noninterventional
study was undertaken to record and evaluate baseline patient
characteristics, and the general safety and effectiveness of sorafenib,
in a broad population of patients with advanced RCC treated in
routine clinical practice.
Patients and Methods
Design and Patients
PREDICT was a prospective, open-label, noninterventional,
noncontrolled, multicenter study conducted from July 2006 to
September 2010 in 18 countries (Argentina, Austria, China,
Colombia, Czech Republic, France, Germany, Greece, Indonesia,
South Korea, Mexico, The Netherlands, The Philippines,
Poland, The Russian Federation, Slovakia, Slovenia, and Sweden;
ClinicalTrials.gov identiﬁer: NCT00895674). Patients were eligible
if they had a diagnosis of advanced RCC and the investigator had
decided to prescribe sorafenib. Physicians were required to consultthe full sorafenib prescribing information before enrolling patients,
and to familiarize themselves with the safety information on the
product package label. There were no protocol-deﬁned exclusion
criteria other than the contraindications for sorafenib, as described
in the appropriate local product information. Institutional review
board approval was not required at the start of the study, except for
countries with different local laws, because treatment was on-label
(patients were excluded if sorafenib was not prescribed according
to the local product information), additional investigations were not
performed, and it was not proposed to allocate patients systemati-
cally to treatment.
Follow-up visits were documented every 2 to 4 months,
depending on the patient’s visit schedule, until the last study visit.
The last study visit was deﬁned as that occurring after approximately
12 months, at discontinuation of therapy, or at the end of the study,
whichever occurred ﬁrst. However, documentation of ﬁnal visits
after 12 months was accepted, and patients with ﬁnal visits occur-
ring beyond 12 months were not excluded from the analyses. At the
last study visit, the physician reported whether sorafenib would be
continued; if it was not, then the reason for discontinuation was
recorded.
Treatment
All patients were treated with sorafenib. The dose prescribed was at
the treating physician’s discretion; however, physicians were advised to
comply with the recommendations in the local product informa-
tion. The duration of treatment was at the discretion of the physician.
Assessments
Study assessments included demographic data and baseline
characteristics, treatment duration, concomitant medications, and
efﬁcacy and safety variables. The treatment duration was deﬁned as
the interval from the ﬁrst dose to the last dose, the end of the study
period, or death. Overall survival data were unavailable, because the
patients were not followed up after the study. Tumor response was
determined using clinical assessments and radiologic assessments
according to the Response Evaluation Criteria In Solid Tumors
(RECIST). Scheduling of follow-up visits was not predeﬁned by the
protocol. PFS was deﬁned as the time from the initial visit to disease
progression or death from any cause, whichever occurred ﬁrst. PFS
calculation was based on radiologic assessment of tumor status
according to RECIST. If radiologic ﬁndings were not available, then
the clinical tumor status evaluation was applied. Adverse events
(AEs) were summarized for the safety population using the Medical
Dictionary for Regulatory Activities coding system. AE reporting
included the National Cancer InstituteeCommon Terminology
for Adverse Events Criteria grade, relationship to study treatment,
seriousness, action taken, and outcome. The relationship to the
study drug was determined by the investigator. Investigator-assessed,
subjective determinations of efﬁcacy and tolerability were recorded at
the follow-up and ﬁnal visits. Because this was a noninterventional
study, no additional diagnostic or monitoring procedures outside of
local standard clinical practice were required.
Statistical Analysis
The safety analysis included all patients who had received  1
dose of sorafenib and who had  1 follow-up visit. The efﬁcacyClinical Genitourinary Cancer April 2015 - 157
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158 -analysis included all patients who had received  1 dose of
sorafenib and who had efﬁcacy data recorded at the initial visit
and at a minimum of 1 follow-up visit after 1 month of treat-
ment. Demographic data, baseline characteristics, and other
outcome variables were described for the efﬁcacy population us-
ing summary statistics (mean, standard deviation [SD] and
median for continuous variables, and category counts and fre-
quencies [percentages] for categorical variables). PFS was initially
analyzed only among those patients with documented disease
progression or death during the follow-up period, with other
patients considered as missing. In a subsequent analysis, patients
with no documented progression or death during the follow-up
period were included and were censored at their last follow-up
visit.Figure 1 Patient Flow
Abbreviations: MSKCC ¼ Memorial Sloan-Kettering Cancer Center; RCC ¼ renal cell carcinoma.
aOnly 1 reason for exclusion was picked if > 1 reason for exclusion was found.
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Patients
A total of 2855 patients entered the study, of whom 2599 were
included in the safety population and 2311 in the efﬁcacy popu-
lation (Figure 1). The most frequent reasons for exclusion from the
safety population were lack of a follow-up visit (n ¼ 143), multiple
participation in clinical studies (n ¼ 57), and retrospective
recruitment (n ¼ 37). The most frequent reasons for exclusion from
the efﬁcacy population were a lack of documented metastases at the
start of sorafenib treatment (n ¼ 130), no follow-up visit after  1
month of treatment (n ¼ 79), and an indication for treatment that
was not RCC (n ¼ 67). Most patients included in the efﬁcacy
population were male (71%), and 23% were aged  70 years
(Table 1). The multiethnic patient population was 52% white and
Table 1 Demographic and Baseline Characteristics (Efﬁcacy
Population)
Variable
PREDICT
(n [ 2311)
TARGET2
(n [ 451)a
Male sex 1644 (71) 315 (70)
Ageb (Years)
Median 60 58
Range 17-88 19-86
Age group
< 70 years 1765 (76) 381 (84)
 70 years 532 (23) 70 (16)
Race
White 1208 (52) 334 (74)
Asian 917 (40) 4 (< 1)
Black 5 (< 1) 2 (< 1)
Other or missingc 181 (8) 111 (25)
Nephrectomy 1947 (84) 422 (94)
Clear cell histologic features only 1928 (83) 449 (> 99)
ECOG PS
0 463 (20) 219 (49)
1 1185 (51) 223 (49)
2 523 (23) 7 (< 1)
> 2 136 (6) Excluded
Metastasis
At baseline
1 Location 1232 (53) 62 (14)
> 1 Location 1079 (47) 387 (86)
Location
Lung 1639 (71) 348 (77)
Bone 635 (28) 110 (25)
Liver 478 (21) 116 (26)
Brain 113 (5) Excluded
MSKCC prognostic risk
Low 472 (20) 233 (52)
Intermediate 824 (36) 218 (48)
High 252 (11) Excluded
Not assessed 718 (31) 0
Previous systemic anticancer therapy 1454 (63) 451 (100)
Last therapy received
Solely cytokine-based 952 (41) 374 (83)
Targeted therapy 227 (10) NA
Sunitinib 209 (9)
Temsirolimus 9 (< 1)
Pazopanib 8 (< 1)
Bevacizumab plus interferon 2 (< 1)
Table 1 Continued
Variable
PREDICT
(n [ 2311)
TARGET2
(n [ 451)a
Speciﬁc medical historyd NA
Hypertension 674 (29.2)
Diabetes mellitus 225 (9.7)
Heart failure 86 (3.7)
Angina pectoris 60 (2.6)
Myocardial infarction 51 (2.2)
Previous handefoot skin reaction 43 (1.9)
Ischemic stroke 30 (1.3)
Leukocytopenia 23 (1.0)
Data presented as n (%), unless otherwise noted.
Abbreviations: ECOG PS ¼ Eastern Cooperative Oncology Group performance status;
MSKCC ¼ Memorial Sloan-Kettering Cancer Center; NA ¼ not applicable;
PREDICT¼ Patient characteristics in REnal cell carcinoma and Daily practICe Treatment with sorafenib;
TARGET ¼ Treatment Approaches in Renal cancer Global Evaluation Trial.
aPatients randomized to sorafenib.
bAge at baseline was missing for 14 patients.
cCollection of racial data not permitted in some countries.
dSpeciﬁc concomitant diseases or conditions in  1% of patients at entry.
D. Jäger et al40% Asian. Notable proportions of patients had ECOG PS 2 or
> 2. Hypertension was the most common comorbidity, followed by
diabetes mellitus (Table 1); other concomitant diseases tended to be
cardiovascular.
Most patients had clear-cell histologic features only (Table 1).
Almost one half of patients had > 1 metastatic disease location, andmost patients had lung metastases. Brain metastases were present in
5% of the patients. The Memorial Sloan-Kettering Cancer Center
(MSKCC) risk was high in 11% of patients but was not assessed in
31% of patients.
Most patients had undergone nephrectomy. About one third of
patients were receiving sorafenib as ﬁrst-line systemic therapy. The
last therapy received was solely cytokine-based for most previously
treated patients (952 of 1454, 65%). For 227 of 1454 patients (16%),
targeted therapy (sunitinib, temsirolimus, pazopanib, or bevacizumab
plus interferon) was the last therapy before sorafenib.
Treatment Patterns
The median interval between follow-up visits was 2 months, until
visit 5. Most patients (2105 of 2311, 91%) initiated sorafenib
therapy at the recommended dose (400 mg twice daily [b.i.d.];
Figure 2); 72% of these patients (1519 of 2105) also received
sorafenib 400 mg b.i.d. as their last dose. The last dose was not
documented for 241 patients (10%). Younger patients (< 70 years)
tended to start and end treatment with sorafenib 400 mg b.i.d. A
greater proportion of elderly patients ( 70 years) than younger
patients received once-daily sorafenib 400 mg as the ﬁrst and/or last
dose (Figure 2).
Duration of Therapy
The median duration of therapy for the total patient population
was 7.3 months (range, 0.1-48.6 months). The median duration of
therapy in several clinically relevant patient subgroups was generally
similar to, or slightly shorter than, that in the overall study population
(Figure 3). This was true, in particular, for patients with ECOG PS 2,
those with brain metastases, and those with prior systemic anticancer
therapy. Themedian duration of therapy for patients with a history of
hypertension or diabetes was also within several weeks of that for the
overall population. The median duration of therapy tended to be
slightly shorter in patients with bone or liver metastases, with
multiple baseline metastases, and with no prior nephrectomy, and for
those aged 70 years, and was considerably shorter for patients withClinical Genitourinary Cancer April 2015 - 159
Figure 2 Initial and Final Sorafenib Doses Received (Efﬁcacy
Population)
Abbreviations: b.i.d. ¼ twice daily; q.d. ¼ once daily.
aA total of 2261 patients had sorafenib 400 mg b.i.d. or q.d. as the initial dose; 1954 patients
had sorafenib 400 mg b.i.d. or q.d. as the ﬁnal dose; the remaining patients had either received
a different dose as their initial and/or ﬁnal dose or the dose data were missing.
bAge at baseline was missing for 14 patients.
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160 -ECOG PS 3 and patients with non-clear-cell histologies, than in the
overall population. For patients who had received prior targeted
therapy, principally sunitinib, the median duration of therapy was
shorter than for the others.
In total, 1274 patients discontinued treatment at the ﬁnal study
visit. The reasons for discontinuation included disease progression
(781 patients [34% of the efﬁcacy population]), patient decision
(192 patients [8%]), death (170 patients [7%]), AE or toxicity (157
patients [7%]), lost to follow-up (68 patients [3%]), and other (50
patients [2%]). Patients could have multiple reasons for dis-
continuing sorafenib.
The number of patients followed up for > 12 months was
calculated based on the ﬁnal visit date. In all, 537 patients (23%)
had a ﬁnal visit > 12 months after their initial visit.
Tumor Response and PFS
There was no speciﬁc schedule for tumor evaluation by
investigators; however,> 80%of patients had computed tomography
scan evaluations at least twice during the study (at baseline and the last
visit). In the efﬁcacy population, the response rate (complete response
plus partial response) was 23.4%, and the disease control rate (com-
plete response plus partial response plus stable disease) was 70.4%
(Table 2). However, 592 patients had no radiologic assessment;
when these patients were excluded, the response rate for the remainder
(n¼ 1719) was 31.4%, and the disease control rate was 94.6%. New
metastases were rarely detected at any time during the study period
(bone, 3.1% of patients [n ¼ 71]; brain, 1.6% [n ¼ 37]; liver, 3.0%
[n ¼ 70]; lung, 2.3% [n ¼ 54]; kidney, 0.6% [n ¼ 15]).
The mean PFS  SD since the start of sorafenib therapy in the
1094 patients with documented disease progression during follow-
up was 6.0  4.3 months (median, 5.0 months; range, 0.2-26.7
months). There was no documented disease progression during
follow-up for 1001 patients. Median PFS, including the censoredClinical Genitourinary Cancer April 2015data from these patients, was 7.3 months; mean PFS  SD was 8.0
 5.0 months. For patients receiving no previous systemic anti-
cancer therapy (n ¼ 760), the median PFS was 7.6 months (mean
PFS, 8.1  5.0 months), and for patients receiving  1 previous
therapies (n ¼ 1333), the median PFS was 7.1 months (mean PFS,
7.9  5.0 months). No data were available regarding overall sur-
vival; however, during the study period, 280 patients in the safety
population died (11%) of any cause (n ¼ 2599).
Tolerability
In the safety population, 57% of patients (1479 of 2599) had any
AE and 48% (1240 of 2599) had any drug-related AE (DRAE).
Serious AEs were reported in 18% of patients (477 of 2599), with
drug-related serious AEs in 5% (140 of 2599). The most frequent
DRAEswere handefoot skin reaction (HFSR, 20%), diarrhea (17%),
and rash (8%; Table 3). These were also the most frequent drug-
related serious AEs, although they affected few patients (Table 3).
Patients were asked about symptoms affecting their daily life
(dyspnea, cough) and their ability to work. These generally
remained unchanged between the ﬁrst and last visits (Table 4).
However, improvements were recorded for dyspnea in 9% of pa-
tients, cough in 10% of patients, and ability to work in 7%. The
status was unknown for approximately 20% of patients for each
condition.
Investigator Assessment of Efﬁcacy and Tolerability
Efﬁcacy was rated by the investigators as “very good” or “good”
for > 70% of patients at each of the ﬁrst 5 follow-up visits
(Supplemental Table 1 is available in the online version). During
the same period, safety was rated as “very good” or “good” for
> 60% of patients. At the ﬁnal visit, efﬁcacy and tolerability were
each assessed as “very good” or “good” for approximately one half of
patients.
Changes in ECOG PS
Most patients who had ECOG PS 1 to 4 at baseline had an
unchanged or improved PS over the course of the study. Of those
patients with PS 1 at baseline, the PS remained unchanged or
improved during the study period for 60% (710 of 1185). For
patients with ECOG PS 2, 3, and 4, the proportions of patients
whose scores were unchanged or improved were 66% (344 of 523),
55% (65 of 118), and 78% (14 of 18), respectively.
Discussion
In the noninterventional PREDICT study, sorafenib was
administered in routine clinical practice to a broad population of
patients with advanced RCC, including patients who would
generally be excluded from phase III clinical studies. Importantly,
sorafenib was generally well tolerated and provided clinical beneﬁt
in this population.
Because this was a noninterventional study, with no additional
diagnostic or monitoring procedures beyond standard local clinical
practice, the data are subject to some limitations. Data collection
relied on submission of paper-based documentation; therefore,
the number of patients excluded for not meeting the protocol
requirements was relatively high, and many patients did not have
any follow-up visits. PFS was not a predeﬁned study endpoint, and
Figure 3 Duration of Sorafenib Therapy
Abbreviations: ECOG PS ¼ Eastern Cooperative Oncology Group performance status; MSKCC ¼ Memorial Sloan-Kettering Cancer Center; SD ¼ standard deviation.
aDuration of therapy was not available for 6 patients in the efﬁcacy population (n ¼ 2311).
bPatients who continued therapy beyond the ﬁnal study visit; for the patients who continued therapy, the ﬁnal visit was recorded as the last dose for the duration of therapy calculations.
D. Jäger et alclinical data and investigator assessments were neither rigorously
collected nor validated by a central reviewer. Also, because the study
was closed when the last patient had completed 12 months of
follow-up (or had discontinued earlier), some patients were not
followed up until progression or death. Therefore, precision in the
estimate of duration of therapy and PFS was limited, despite
applying appropriate censoring. Regardless of these limitations,
which are common to all noninterventional studies, the results of
the PREDICT study provide valuable insight into the treatmentoutcomes in a real-world setting, where there is less standardization
of assessments and patient populations are highly heterogeneous.
The diversity of the PREDICT study population is particularly
evident when compared with the phase III TARGET study popu-
lation (Table 1).2 PREDICT enrolled greater proportions of
nonwhite patients and those with poor ECOG PS ( 2), and lower
proportions of patients with prior nephrectomy or prior systemic
therapy. PREDICT also included patients who would have been
ineligible for TARGET, such as those with brain metastases,Clinical Genitourinary Cancer April 2015 - 161
Table 2 Best Tumor Response (Excluding Initial Visit; Efﬁcacy
Population)a
Best Response n %
Total 2311 100.0
Complete response 40 1.7
Partial response 500 21.6
Stable disease 1086 47.0
Disease control rateb 1626 70.4
Progressive disease 93 4.0
No radiologic assessment 592 25.6
aBased on investigator assessment using the Response Evaluation Criteria In Solid Tumors.
bDisease control rate was deﬁned as all patients with a complete response, partial response, or
stable disease.
Table 4 Change in Patient Assessment of Parameters
Affecting Daily Life (Last Visit Compared With Initial
Visit; Efﬁcacy Population; n [ 2311)a
Condition Unchanged Worsened Improved Unknown
Dyspnea 1388 (60.1) 293 (12.7) 202 (8.7) 428 (18.5)
Cough 1401 (60.6) 245 (10.6) 235 (10.2) 430 (18.6)
Ability to workb 981 (42.4) 204 (8.8) 159 (6.9) 472 (20.4)
Data presented as n (%).
aPatients were queried at the initial and follow-up visits; for dyspnea and cough, patient status
was “no,” ”little,” or “much.”
bAbility to work was not applicable for 495 patients; the queried categories were “full time,”
“part time,” “no,” and “not applicable.”
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162 -non-clear-cell histologies, or a high MSKCC risk score. Patients
with advanced RCC who would generally be ineligible for clinical
trials have markedly shorter PFS and overall survival than patients
eligible for clinical trials.15 It is, therefore, important to evaluate
targeted therapies in diverse patient populations to ensure that the
ﬁndings from randomized, controlled trials translate into clinical
practice, as was found in the present study. The efﬁcacy and safety
results of the PREDICT study are consistent with the results from
the phase III TARGET study and the sorafenib expanded access
programs.16-18
The duration of therapy is routinely available from patient
records and is therefore a reliably recorded outcome for patients in aTable 3 Most Commonly Reported Drug-Related Adverse
Events (Occurring in ‡ 2% of Patients) and Drug-
Related Serious Adverse Events (Reported in ‡ 5
Patients; Safety Population [n [ 2599])
Adverse Event n %
Drug-related
Handefoot skin reactiona 520 20.0
Diarrhea 443 17.0
Rashb 220 8.5
Alopecia 145 5.6
Hypertension 110 4.2
Fatigue 88 3.4
Decreased appetite 76 2.9
Nausea 67 2.6
Pruritus 58 2.2
Erythema 54 2.1
Drug-related serious
Handefoot skin reactiona 15 0.6
Diarrhea 12 0.5
Rashb 12 0.5
Vomiting 8 0.3
Dyspnea 6 0.2
Pyrexia 6 0.2
Nausea 5 0.2
aPalmareplantar erythrodysesthesia syndrome.
bIncluding rash generalized, rash erythematous, rash maculopapular, rash pustular, rash
macular, rash pruritic, exfoliative rash, and rash papular.
Clinical Genitourinary Cancer April 2015large observational study. A long duration of therapy suggests both
effectiveness and tolerability of a treatment. Because radiologic
assessment of disease progression was not required in PREDICT,
some patients may have continued therapy beyond progression or
because of a lack of treatment alternatives. Likewise, some patients
may have had clinical beneﬁt but discontinued therapy owing to
toxicity or personal preference. Nonetheless, in PREDICT, the
median duration of therapy (7.3 months) compares reasonably well
with the median PFS of 7.3 months, including censored patients
(5.0 months for patients with documented progression). In other
randomized clinical trials, in which therapy was generally termi-
nated once progression was detected, the median duration of sor-
afenib therapy also tended to be similar to the median PFS (5.3 and
5.5 months, respectively, in TARGET2; 5.0 and 4.7 months in the
phase III AXIS (“axitinib vs. sorafenib in advanced renal cell car-
cinoma”) study7; and 6.0 and 5.7 months in the phase II trial of
sorafenib vs. interferon-a19). Therefore, it might be reasonable to
suggest that duration of therapy for patients in PREDICT is an
indirect measure of sorafenib efﬁcacy.
The median duration of therapy in the overall PREDICT pop-
ulation was generally similar across several clinically relevant sub-
groups, including those with brain metastases or with ECOG PS 2.
The duration of therapy tended to be slightly shorter for patients
with ECOG PS 3; this was to be expected, as a higher ECOG PS is
a marker of poorer prognosis.20 Approximately one quarter of
PREDICT patients received sorafenib for > 12 months, suggesting
that sorafenib might provide durable beneﬁt in some patients.
Consistent with our observation, in a pooled analysis of data from 8
clinical studies (including TARGET and 2 expanded-access studies),
707 of 4684 patients (15%) received sorafenib for > 12 months.21
In PREDICT, the overall response rate was 23% and the disease
control rate was 70%, increasing to 31% and 95%, respectively,
when only those patients with evaluable radiologic assessments were
considered. These rates are greater than those in TARGET2 or in
the phase II sorafenib versus interferon-a trial19; however, response
rates of 9% to 30% have been reported for ﬁrst- and second-line
sorafenib in other randomized trials.7,22-24 Nevertheless, one limi-
tation of observational studies such as PREDICT is that the
response rates and PFS are based on the physician assessment of
tumor status and are not veriﬁed centrally. Additional, subjective
efﬁcacy assessments in PREDICT also suggested that sorafenib was
effective in patients with RCC in clinical practice. Investigators
rated sorafenib efﬁcacy as “good” or “very good” in > 70% of
D. Jäger et alpatients at each of visits 1 to 5, and ECOG PS tended to remain
unchanged or to improve over the course of the study.
PREDICT included many previously untreated patients. The
median PFS was 7.6 months for previously untreated patients and
7.1 months for patients who had received prior systemic anticancer
therapy; the median duration of therapy was 7.5 and 7.2 months,
respectively. These median PFS and duration of therapy ﬁndings are
within the 5.7- to 9.1-month median PFS range previously reported
for ﬁrst-line sorafenib.4,19,22-24 The median duration of therapy for
patients receiving sorafenib after sunitinib was somewhat shorter
than that for the entire population; however, the duration of
previous therapy was not captured. This could reﬂect the emergence
of cross resistance or it might be a consequence of diminishing
efﬁcacy with the line of treatment. Several retrospective and pro-
spective studies have shown that sequential treatment with sorafenib
and sunitinib provides clinical beneﬁt.6,7,25-30 In most of these
studies, the PFS with the second-line agent was shorter than the PFS
reported for the ﬁrst-line treatment. In the SWITCH-1 study, the
ﬁrst randomized, phase III clinical study to prospectively investigate
the sequential use of TKIs, the PFS for sorafenib after sunitinib was
shorter than the PFS for ﬁrst-line sorafenib, and the same was true
for sunitinib administered before or after sorafenib.29
Treatment of advanced RCC has been an area of active research,
and multiple agents have been variously approved worldwide.
Sorafenib has been used as a comparator in all lines of therapy in a
number of trials. Across 2 recent phase III trials (AGILE 105131 and
TIVO-14), the median PFS in treatment-naive patients treated with
sorafenib was 6.5 and 9.1 months, respectively, compared with 10.1
months (axitinib) and 12.7 months (tivozanib). Overall survival was
not mature when the AGILE 1051 ﬁndings were reported. In the
TIVO-1 trial, a trend was seen toward longer overall survival in the
sorafenib arm than in the tivozanib arm (median, 29.3 vs. 28.8
months; hazard ratio [HR], 1.245; 95% conﬁdence interval [CI],
0.954-1.624; P ¼ .105). In 2 recent phase III trials in the second-
line setting after ﬁrst-line sunitinib (INTORSECT6 [temsirolimus
vs. sorafenib as second-line therapy in patients with advanced
RCC who have failed ﬁrst-line sunitinib] and a subgroup of AXIS7),
the median PFS was 3.4 to 3.9 months (sorafenib), 4.3 months
(temsirolimus), and 4.8 months (axitinib). The overall survival was
signiﬁcantly longer with sorafenib than with temsirolimus in the
INTORSECT (16.6 vs. 12.3 months; HR, 1.31; 95% CI, 1.05-
1.63; P ¼ .01),6 and no difference was seen between sorafenib and
axitinib after ﬁrst-line sunitinib in AXIS (16.5 vs. 15.2 months;
HR, 0.997; 95% CI, 0.782-1.270; P ¼ .49).30 In the third-line
setting, for which there is no approved agent, treatment of patients
who had received 1 previous vascular endothelial growth factor-
targeted therapy and 1 previous mammalian target of rapamycin
inhibitor with the exploratory agent dovitinib or sorafenib resulted
in similar outcomes in terms of the median PFS (3.7 vs. 3.6 months;
HR, 0.86; 95% CI, 0.72-1.04; P ¼ .063) and median overall sur-
vival (11.1 vs. 11.0 months; HR, 0.96; 95% CI, 0.75-1.22).5
Sorafenib was well tolerated in PREDICT. The overall rate of
DRAEs was somewhat lower than in clinical studies of sorafenib,3,16
although the incidence data could not be compared directly owing
to the different study designs. Nonetheless, the DRAE proﬁle for
sorafenib in PREDICT was similar in TARGET, NA-ARCCS, and
EU-ARCCS. The most common DRAEs in these trials includedHFSR, diarrhea, rash, and fatigue. The sorafenib DRAE proﬁle was
further analyzed using a large pooled integrated database of 4684
patients who were receiving sorafenib monotherapy for advanced
RCC.32 This analysis of 8 company-sponsored phase I to III clinical
studies, including TARGET, NA-ARCCS, and EU-ARCCS,
demonstrated that DRAEs typically occurred during the ﬁrst 3
months and declined thereafter. Although the PREDICT study
included a broader patient population than the clinical trials, no
unexpected AEs were observed compared with the analysis of the
pooled integrated database. Thus, the favorable sorafenib tolerability
proﬁle observed in clinical studies appears to translate into clinical
practice. This is important, because a predictable safety proﬁle
enables physicians and nurses to monitor for anticipated AEs. In
addition, there are now established strategies to manage commonly
observed AEs.33-35 Effective monitoring and management of AEs
ensures that patients remain on treatment at the recommended
sorafenib dose for as long as possible.Conclusion
The PREDICT study assessed the efﬁcacy and safety of sorafenib
for the treatment of advanced or metastatic RCC in a heteroge-
neous mix of patients, including those who would have been
ineligible for inclusion in phase III studies. The study has
demonstrated that sorafenib is generally well tolerated and provides
clinical beneﬁt in the clinical practice setting. Median duration of
sorafenib therapy was similar across several clinically relevant sub-
groups, and approximately one quarter of patients received sor-
afenib for > 12 months. These results are consistent with other
clinical studies and suggest that sorafenib might provide durable
beneﬁt in patients with advanced RCC. In addition, the median
PFS and duration of therapy for patients receiving ﬁrst-line
sorafenib was within the 5.7- to 9.1-month median PFS range
previously reported for ﬁrst-line sorafenib. Response rates among
patients with evaluable radiologic assessments were also consistent
with those from other clinical studies. Although these efﬁcacy data
are limited by the lack of standardized assessments (required for a
noninterventional study), the data do provide an additional level of
conﬁdence that the results of clinical studies of sorafenib can
translate into the real-world setting. Importantly, the DRAE proﬁle
for sorafenib in this diverse patient population was also similar
to that observed in clinical studies and no unexpected AEs
were observed. This predictable and manageable safety proﬁle of
sorafenib is reassuring; established AE management strategies
continue to be appropriate for ensuring that patients can remain on
treatment for as long as possible to achieve maximum clinical
beneﬁt.Clinical Practice Points
 In phase III clinical studies, sorafenib has demonstrated clinical
efﬁcacy and a manageable safety proﬁle in patients with meta-
static or advanced RCC, as ﬁrst-, second-, and third-line therapy.
 Because patient populations in randomized clinical trials are
limited by extensive inclusion and exclusion criteria, it is
important to evaluate therapies in more diverse patient pop-
ulations to ensure that the ﬁndings from clinical trials translate
into clinical practice.Clinical Genitourinary Cancer April 2015 - 163
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164 - Two large sorafenib expanded-access programs conﬁrmed the
efﬁcacy and safety proﬁle of sorafenib in a much broader pop-
ulation of patients; however, the exclusion criteria in these
studies still resulted in somewhat restricted patient populations.
 The PREDICT study had no exclusion criteria (other than
contraindications described in the appropriate local sorafenib
prescribing information) and thus included a population fully
representative of routine clinical practice.
 The results of the PREDICT study suggest that sorafenib is
generally well tolerated and provides clinical beneﬁt for patients
with advanced RCC in routine clinical practice.
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Supplemental Table 1 Investigator Assessment of Efﬁcacy and Tolerability (Efﬁcacy Population, n [ 2311)
Follow-Up Visit
Median Duration
From Initial Visit
to Follow-up
Visit (d) Very Good Good Sufﬁcient Insufﬁcient Missing
Efﬁcacy
First (n ¼ 1989) 62 414 (21) 1000 (50) 418 (21) 90 (5) 67 (3)
Second (n ¼ 1455) 123 398 (27) 746 (51) 228 (16) 53 (4) 30 (2)
Third (n ¼ 956) 184 245 (26) 509 (53) 148 (15) 42 (4) 12 (1)
Fourth (n ¼ 696) 246 180 (26) 386 (55) 101 (15) 22 (3) 7 (1)
Fifth (n ¼ 507) 308 129 (25) 291 (57) 63 (12) 19 (4) 5 (1)
Sixth (n ¼ 58) 348 16 (28) 31 (53) 10 (17) 1 (2) 0
Last (n ¼ 2084) 232 236 (11) 745 (36) 426 (20) 570 (27) 107 (5)
Tolerability
First (n ¼ 1989) 62 329 (17) 941 (47) 513 (26) 184 (9) 22 (1)
Second (n ¼ 1455) 123 263 (18) 733 (50) 361 (25) 81 (6) 17 (1)
Third (n ¼ 956) 184 174 (18) 491 (51) 237 (25) 44 (5) 10 (1)
Fourth (n ¼ 696) 246 127 (18) 369 (53) 167 (24) 26 (4) 7 (1)
Fifth (n ¼ 507) 308 99 (20) 280 (55) 102 (20) 22 (4) 4 (1)
Sixth (n ¼ 58) 348 7 (12) 22 (38) 23 (40) 6 (10) 0
Last (n ¼ 2084) 232 221 (11) 820 (39) 703 (34) 242 (12) 98 (5)
Data presented as n (%), unless otherwise noted.
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